JP2011527332A - ピペリジンｇｐｃｒ作動薬 - Google Patents

ピペリジンｇｐｃｒ作動薬 Download PDF

Info

Publication number
JP2011527332A
JP2011527332A JP2011517246A JP2011517246A JP2011527332A JP 2011527332 A JP2011527332 A JP 2011527332A JP 2011517246 A JP2011517246 A JP 2011517246A JP 2011517246 A JP2011517246 A JP 2011517246A JP 2011527332 A JP2011527332 A JP 2011527332A
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound
formula
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011517246A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011527332A5 (enExample
Inventor
リサ・サラ・バートラム
マシュー・コリン・ソーア・ファイフ
レバティ・ペルペチュア・ジーヴァラトナム
ジョン・カイリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prosidion Ltd
Original Assignee
Prosidion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0812640A external-priority patent/GB0812640D0/en
Priority claimed from GB0902796A external-priority patent/GB0902796D0/en
Application filed by Prosidion Ltd filed Critical Prosidion Ltd
Publication of JP2011527332A publication Critical patent/JP2011527332A/ja
Publication of JP2011527332A5 publication Critical patent/JP2011527332A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
JP2011517246A 2008-07-10 2009-07-10 ピペリジンｇｐｃｒ作動薬 Withdrawn JP2011527332A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0812640A GB0812640D0 (en) 2008-07-10 2008-07-10 Compounds
GB0812640.1 2008-07-10
GB0902796A GB0902796D0 (en) 2009-02-20 2009-02-20 Compounds
GB0902796.2 2009-02-20
PCT/GB2009/050826 WO2010004344A1 (en) 2008-07-10 2009-07-10 Piperidine gpcr agonists

Publications (2)

Publication Number Publication Date
JP2011527332A true JP2011527332A (ja) 2011-10-27
JP2011527332A5 JP2011527332A5 (enExample) 2012-08-16

Family

ID=41077623

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011517246A Withdrawn JP2011527332A (ja) 2008-07-10 2009-07-10 ピペリジンｇｐｃｒ作動薬

Country Status (7)

Country Link
US (1) US20110230507A1 (enExample)
EP (1) EP2321308B9 (enExample)
JP (1) JP2011527332A (enExample)
CN (1) CN102089301A (enExample)
AT (1) ATE557024T1 (enExample)
ES (1) ES2387865T3 (enExample)
WO (1) WO2010004344A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0904287D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904285D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904284D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
TW201111361A (en) 2009-06-24 2011-04-01 Boehringer Ingelheim Int New compounds, pharmaceutical composition and methods relating thereto
US8481731B2 (en) 2009-06-24 2013-07-09 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical composition and methods relating thereto
JP2013522279A (ja) 2010-03-18 2013-06-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連状態の治療で用いるｇｐｒ１１９作動薬とｄｄｐ−ｉｖ阻害薬リナグリプチンの組合せ
GB201006166D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB201006167D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
CN103080101A (zh) 2010-05-17 2013-05-01 阵列生物制药公司 作为gpr119调节剂的哌啶基取代的内酰胺
TW201209054A (en) 2010-05-28 2012-03-01 Prosidion Ltd Novel compounds
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
SG188985A1 (en) * 2010-09-17 2013-05-31 Array Biopharma Inc Piperidinyl-substituted lactams as gpr119 modulators
GB201114389D0 (en) 2011-08-22 2011-10-05 Prosidion Ltd Novel compounds
WO2012066077A1 (en) 2010-11-18 2012-05-24 Prosidion Limited 1,4 di substituted pyrrolidine - 3 - yl -amine derivatives and their use for the treatment of metabolic disorders
AU2012240122B2 (en) 2011-04-08 2016-08-25 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
EP2720544B1 (en) 2011-06-16 2016-12-21 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760855B1 (en) 2011-09-30 2017-03-15 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds as well as their use in treating type-2 diabetes
EP2771000B1 (en) 2011-10-24 2016-05-04 Merck Sharp & Dohme Corp. Substituted piperidinyl compounds useful as gpr119 agonists
US9018224B2 (en) 2011-11-15 2015-04-28 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds useful as GPR119 agonists

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100042A (en) * 1993-03-31 2000-08-08 Cadus Pharmaceutical Corporation Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
EP0934941A1 (en) * 1996-08-09 1999-08-11 Eisai Co., Ltd. Benzopiperidine derivatives
US6221660B1 (en) * 1999-02-22 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding SNORF25 receptor
DOP2006000008A (es) * 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
MX2007016508A (es) * 2005-06-30 2008-03-04 Prosidion Ltd Agonistas del receptor acoplado a la proteina g.
US20100048625A1 (en) * 2007-01-04 2010-02-25 Matthew Colin Thor Fyfe Piperidine gpcr agonists
GB0700122D0 (en) * 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
GB0812648D0 (en) * 2008-07-10 2008-08-20 Prosidion Ltd Compounds

Also Published As

Publication number Publication date
CN102089301A (zh) 2011-06-08
EP2321308B9 (en) 2012-08-08
ATE557024T1 (de) 2012-05-15
WO2010004344A1 (en) 2010-01-14
HK1158192A1 (en) 2012-07-13
EP2321308B1 (en) 2012-05-09
ES2387865T3 (es) 2012-10-03
EP2321308A1 (en) 2011-05-18
US20110230507A1 (en) 2011-09-22

Similar Documents

Publication Publication Date Title
JP2011527332A (ja) ピペリジンｇｐｃｒ作動薬
JP4916452B2 (ja) Ｇｐｃｒ作動薬としてのピリジン、ピリミジン、およびピラジンの誘導体
EP2114931B1 (en) Piperidine gpcr agonists
EP2318399B1 (en) Piperidinyl gpcr agonists
EP2114935B1 (en) Piperidine gpcr agonists
JP2011527331A (ja) ピペリジニルｇｐｃｒ作動薬
JP2011527334A (ja) ヘテロ環式ｇｐｃｒ作動薬
JP2010514832A (ja) ピペリジンｇｐｃｒアゴニスト
JP2009533410A (ja) Ｇタンパク質共役型受容体（ｇｐｒ１１９）アゴニストとしてのアゼチジン誘導体
JP2010514830A (ja) ピペリジンｇｐｃｒアゴニスト
JP2011527335A (ja) ヘテロ環式ｇｐｃｒ作動薬
JP2010514828A (ja) ピペリジンｇｐｃｒアゴニスト
JP2011500658A (ja) アゼチジニルｇタンパク質共役受容体アゴニスト
JP2008545010A (ja) Ｇタンパク質共役受容体アゴニスト
JP2011500659A (ja) アゼチジニルｇタンパク質共役受容体アゴニスト
HK1158192B (en) Piperidine gpcr agonists
HK1157329B (en) Piperidinyl gpcr agonists
HK1135704B (en) Piperidine gpcr agonists
HK1163680A (en) Piperidine gpcr agonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120629

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120629

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20130329